{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:54:40Z","timestamp":1782485680782,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.critrevonc.2021.103509","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T23:10:50Z","timestamp":1634857850000},"page":"103509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["CD200 expression in hematopoietic neoplasms: Beyond a marker for diagnosis of B-cell neoplasms"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9597-7193","authenticated-orcid":false,"given":"Renata B.","family":"Staub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-2082","authenticated-orcid":false,"given":"Nat\u00e1lia A.","family":"Marcondes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-5203","authenticated-orcid":false,"given":"Liane N.","family":"Rotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2021.103509_bib0005","first-page":"665","article-title":"Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma","volume":"137","author":"Aberuyi","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103509_bib0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1309\/AJCP59UORCYZEVQO","article-title":"Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma","volume":"137","author":"Alapat","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103509_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2206","article-title":"Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma","volume":"35","author":"Aref","year":"2017","journal-title":"Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103509_bib0020","doi-asserted-by":"crossref","DOI":"10.31557\/APJCP.2020.21.3.743","article-title":"Clinical significance of CD200 and CD56 expression in patients with acute myeloid leukemia","volume":"21","author":"Aref","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103509_bib0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1471-4906(02)02223-8","article-title":"CD200 and membrane protein interactions in the control of myeloid cells","volume":"23","author":"Barclay","year":"2002","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103509_bib0030","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103509_bib0035","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/leu.2012.77","article-title":"Expression of CD200 on AML blasts directly suppresses memory T-cell function","volume":"26","author":"Coles","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103509_bib0040","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/leu.2015.62","article-title":"The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse","volume":"29","author":"Coles","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103509_bib0045","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.leukres.2013.08.006","article-title":"CD200 expression in patients with Multiple Myeloma: another piece of the puzzle","volume":"37","author":"Conticello","year":"2013","journal-title":"Leuk. Res."},{"issue":"30","key":"10.1016\/j.critrevonc.2021.103509_bib0050","doi-asserted-by":"crossref","first-page":"30212","DOI":"10.18632\/oncotarget.4901","article-title":"Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors","volume":"6","author":"Damiani","year":"2015","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.critrevonc.2021.103509_bib0055","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood.V128.22.4021.4021","article-title":"Investigating the effects of Anti-CD200 therapy for childhood ALL","volume":"128","author":"Diamanti","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103509_bib0060","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1309\/AJCP38XRRUGSQOVC","article-title":"CD200 (OX-2 membrane glycoprotein) expression in B cell-derived neoplasms","volume":"134","author":"Dorfman","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103509_bib0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PAS.0b013e31820065c9","article-title":"CD200 (OX-2 membrane glycoprotein) is expressed by follicular t helper cells and in angioimmunoblastic T-cell lymphoma","volume":"35","author":"Dorfman","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103509_bib0070","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/jclinpath-2014-202421","article-title":"Diagnostic and prognostic significance of CD200 expression and its stability in plasma cell myeloma","volume":"67","author":"Douds","year":"2014","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103509_bib0075","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2353\/ajpath.2007.070474","article-title":"Tickling the CD200 receptor: a remedy for those irritating macrophages","volume":"171","author":"Feuer","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103509_bib0080","first-page":"488","article-title":"Augmented induction of CD4+CD25+ treg using monoclonal antibodies to CD200R","volume":"79","author":"Gorczynski","year":"2005","journal-title":"Transplantation"},{"issue":"21","key":"10.1016\/j.critrevonc.2021.103509_bib0085","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020001802","article-title":"CD200 expression marks leukemia stem cells in human AML","volume":"4","author":"Ho","year":"2020","journal-title":"Blood Adv."},{"issue":"5497","key":"10.1016\/j.critrevonc.2021.103509_bib0090","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1126\/science.290.5497.1768","article-title":"Down-regulation of the macrophage lineage through interaction with OX2 (CD200)","volume":"290","author":"Hoek","year":"2000","journal-title":"Science (80-)."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103509_bib0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/07357907.2012.756110","article-title":"Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression","volume":"31","author":"Jadidi-Niaragh","year":"2013","journal-title":"Cancer Invest."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103509_bib0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4049\/jimmunol.176.1.191","article-title":"Regulation of myeloid cell function through the CD200 receptor","volume":"176","author":"Jenmalm","year":"2006","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103509_bib0105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2010.08127.x","article-title":"Blockade of the MEK\/ERK signalling cascade by AS703026, a novel selective MEK1\/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo","volume":"149","author":"Kim","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103509_bib0110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000252803","article-title":"Expression of the inhibitory CD200 receptor is associated with alternative macrophage activation","volume":"2","author":"Koning","year":"2010","journal-title":"J. Innate Immun."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103509_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22041602","article-title":"Cd200:Cd200r interactions and their importance in immunoregulation","volume":"22","author":"Kotwica-Mojzych","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103509_bib0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14712598.8.1.5","article-title":"Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression","volume":"8","author":"Kretz-Rommel","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103509_bib0125","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.178.9.5595","article-title":"CD200 expression on tumor cells suppresses antitumor immunity: new approaches to Cancer immunotherapy","volume":"178","author":"Kretz-Rommel","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2021.103509_bib0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtbi.2013.03.017","article-title":"The role of CD200-CD200R in tumor immune evasion","volume":"328","author":"Liao","year":"2013","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.critrevonc.2021.103509_bib0135","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-030-35582-1_8","article-title":"CD200-CD200R pathway in the regulation of tumor immune microenvironment and immunotherapy","volume":"1223","author":"Liu","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.critrevonc.2021.103509_bib0140","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.2147\/DDDT.S100062","article-title":"More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis","volume":"10","author":"Lu","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103509_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0710-1","article-title":"Phase i study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200","volume":"7","author":"Mahadevan","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103509_bib0150","first-page":"531","article-title":"Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia","volume":"34","author":"Memarian","year":"2013","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"issue":"13","key":"10.1016\/j.critrevonc.2021.103509_bib0155","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma","volume":"108","author":"Moreaux","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103509_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2007.11.103","article-title":"CD200: A putative therapeutic target in cancer","volume":"366","author":"Moreaux","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103509_bib0165","doi-asserted-by":"crossref","DOI":"10.4103\/ijh.ijh_37_17","article-title":"Evaluation of the expression of CD200 and CD56 in CD34-positive adult acute myeloid leukemia and its effect on the response to induction of chemotherapy","volume":"7","author":"Muhsin","year":"2018","journal-title":"Iraqi J. Hematol."},{"issue":"22","key":"10.1016\/j.critrevonc.2021.103509_bib0170","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2017-04-777052","article-title":"A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia","volume":"130","author":"Oda","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103509_bib0175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2141.2010.08555.x","article-title":"CD200 expression in plasma cell myeloma","volume":"153","author":"Olteanu","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103509_bib0180","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1309\/AJCP3TQR1TFHHGAS","article-title":"CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: Clinicopathologic features and comparison with plasma cell myeloma","volume":"138","author":"Olteanu","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103509_bib0185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.coi.2012.01.002","article-title":"CD200R signaling in tumor tolerance and inflammation: a tricky balance","volume":"24","author":"Rygiel","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.critrevonc.2021.103509_bib0190","article-title":"Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment","author":"Shi","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103509_bib0195","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/ni.1637","article-title":"A critical function for CD200 in lung immune homeostasis and the severity of influenza infection","volume":"9","author":"Snelgrove","year":"2008","journal-title":"Nat. Immunol."},{"issue":"February","key":"10.1016\/j.critrevonc.2021.103509_bib0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.leukres.2017.04.001","article-title":"High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-\/NPM1+ patients","volume":"58","author":"Tiribelli","year":"2017","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103509_bib0205","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1038\/sj.leu.2404961","article-title":"Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia","volume":"21","author":"Tonks","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103509_bib0210","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.leu.2404559","article-title":"CD200 as a prognostic factor in acute myeloid leukaemia [7]","volume":"21","author":"Tonks","year":"2007","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.critrevonc.2021.103509_bib0215","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1182\/blood-2011-07-365817","article-title":"Regulatory T cells in acute myelogenous leukemia: Is it time for immunomodulation?","volume":"118","author":"Ustun","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103509_bib0220","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1189\/jlb.1009686","article-title":"The role of CD200 in immunity to B cell lymphoma","volume":"88","author":"Wong","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.critrevonc.2021.103509_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2017.01.021","article-title":"Over-expression of CD200 predicts poor prognosis in MDS","volume":"56","author":"Xi","year":"2017","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103509_bib0230","doi-asserted-by":"crossref","DOI":"10.3233\/CBM-181368","article-title":"Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia","volume":"22","author":"Zahran","year":"2018","journal-title":"Cancer Biomark."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:42:02Z","timestamp":1760902922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821002961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":46,"alternative-id":["S1040842821002961"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103509","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD200 expression in hematopoietic neoplasms: Beyond a marker for diagnosis of B-cell neoplasms","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103509"}}